GlassScriptPhysician profile
George A Castro
NPI 1992852941
$8,406.16
in general payments reported to CMS, 2019-2025
26 companies · $3,309 in 2025
The $3,309 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.58 · 2020: $101 · 2021: $261 · 2022: $439 · 2023: $1,322 · 2024: $2,880 · 2025: $3,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,427 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,426.98 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,249.29 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,476.59 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Gilead Sciences, INC. | $953.14 | 2021-2025 | Biktarvy |
| Genzyme Corporation | $672.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $509.87 | 2023-2025 | Dupixent |
| Viiv Healthcare Company | $485.73 | 2022-2025 | Apretude |
| Mallinckrodt Hospital Products INC. | $360.24 | 2025 | Acthar |
| Novo Nordisk INC | $277.95 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $236.01 | 2023-2025 | Tezspire |
| Phathom Pharmaceuticals, INC. | $220.22 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.18 | 2022-2025 | Ofev, Jascayd |
| Lilly USA, LLC | $163.02 | 2024-2025 | Zepbound, Mounjaro |
| Verona Pharma, INC. | $132.06 | 2025 | Ohtuvayre |
| Baxter Healthcare | $77.47 | 2023-2024 | Hillrom - Life 2000 Ventilation System |
| Viatris Specialty LLC | $59.23 | 2025 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $56.27 | 2025 | Korlym |
| Pfizer INC. | $53.44 | 2025 | |
| Paratek Pharmaceuticals, INC. | $40.57 | 2025 | Nuzyra |
| Inspire Medical Systems, INC. | $36.76 | 2024 | Inspire |
| Hikma Pharmaceuticals USA | $34.83 | 2023 | Ryaltris |
| Vifor Pharma, INC. | $26.77 | 2024 | Zemaira |
| Abbvie INC. | $24.75 | 2019 | |
| Phadia US INC. | $20.47 | 2025 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.35 | 2019 | |
| Zimmer Biomet Holdings, INC. | $19.16 | 2020 | |
| Electromed, INC. | $17.10 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.